Table 1.

Study Participant Characteristics for CAH and Control Infants

	CAH (n = 16)	Control (n = 14)	Group Difference, p-value
Age at MRI (weeks)
Gestational Age	38.2 ± 1.74	38.5 ± 1.8	0.83a
Post-conceptional Age	42.2 ± 3.0	42.5 ± 2.4	0.88a
Biological sex (n)	Female, 8 Male, 8	Female, 5 Male, 9	0.68b
Hispanic/ Latino (n; %)	6; 37.5%	7; 50%	0.79b
Race (n; %)
White	14; 87.5%	5; 35.7%	0.001b
Asian	2; 12.5%	2; 14.3%
CAH Form (n)
Salt-wasting	15	-	-
Simple-virilizing	1
Glucocorticoid dose (mg/m2/day)	35.2 ± 16.4	-	-
Fludrocortisone dose (mg/day)	0.12 ± 0.04
NaCl dose (mEq/day)	4.27 ± 0.70
CAH Analytes
Newborn screen 17-OHP (ng/dL)	29080.4 ± 14325.2	-	-
Newborn screen 17-OHP [nmol/L]	[881.1 ± 434.1]
Confirmatory serum 17-OHP (ng/dL)	16719.8 ± 11164.5
Confirmatory serum 17-OHP [nmol/L]	[506.6 ± 338.3]
Highest newborn 17-OHP (ng/dL)	28861.9 ± 13996.9
Highest newborn 17-OHP [nmol/L]	[874.5 ± 424.1]
Confirmatory serum testosterone (ng/dL)	289.1 ± 277.7
Confirmatory serum testosterone [nmol/L]	[10.03 ± 9.6]
Confirmatory serum androstenedione (ng/dL)	3674.6 ± 3699.8
Confirmatory serum androstenedione [nmol/L]	[128.2 ± 129.1]
Plasma Renin Activity (ng/mL/hr and μg/L/hr)	50.1 ± 75.4

Mean ± SD

^aWilcoxon sign-rank test;

^bChi-square test